Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Medical Research & Consulting Services LLC currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, PAUL RANDALL GAUGER, who is also identified as the busiest examiner for the company. Prosecution is localized in 1 distinct art unit. With GAUGER, PAUL RANDALL handling 1 busiest examiner pending action, the company's immediate legal focus is limited to a single reviewer.
This lack of examiner diversity means that the progress of the portfolio is tied to the specific habits of one individual. Practitioners should be aware that with only 1 distinct art unit involved, there are no other concurrent applications to provide context on departmental trends. The presence of 1 pending office action indicates a streamlined prosecution profile at this time.
Because the 1 distinct examiner and 1 distinct art unit represent the whole of the pending workload, the strategy must be highly tailored to the Biotechnology & Pharmaceuticals sector's specific requirements. Aligning with the expectations of PAUL RANDALL GAUGER is essential for moving this single pending office action toward allowance. This centralized approach simplifies the management of the portfolio but increases the impact of a single examiner's discretion.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GAUGER, PAUL RANDALL | 1 | 59.3% | +8.3% |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18468510 | HAPH ANALOGS AND THERAPEUTIC AND DIAGNOSTIC USES THEREOF | GAUGER, PAUL RANDALL | 1629 | §102DP | Non-Final OA | — | Pending | Sep 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedical Research & Consulting Services LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul Randall Gauger has the most, with 1 of Medical Research & Consulting Services LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
